Reuters logo
Mylan to buy Abbott's non-US specialty, branded generics assets
July 14, 2014 / 10:41 AM / 3 years ago

Mylan to buy Abbott's non-US specialty, branded generics assets

July 14 (Reuters) - Generic drugmaker Mylan Inc said it would buy Abbott Laboratories’ specialty and branded generics business outside the United States in an all-stock transaction valued at about $5.3 billion.

Abbott will receive 105 million shares of the combined company worth.

Reporting by Shailesh Kuber; Editing by Sriraj Kalluvila

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below